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Abstract — Center for Antibody Production Rijeka (CAPRI) is a part of the Center for Proteomics devoted to 
mouse monoclonal antibody production. The Center for Proteomics is a department at the University of Rijeka 
Faculty of Medicine that is to a large extent self-sustainable since it employs scientists, administrative and 
technical staff and covers all its research costs from competitive international grants which makes it a unique 
department in the Croatian academia. One of the objectives of the Center for Proteomics is to put emphasis on 
applied R&D and utilization of the existing large collection of antibodies and antibody-based products, both 
suitable for further commercial development.
Index Terms — antibodies, antibody based recombinant proteins, cytomegalovirus, varicella zoster virus, 
lymphocyte receptors
_____________________________________________________________________ 
1 BACKGROUND
CAPRI, as a part of the Center for Proteomics, possesses an excellent collection of monoclonal antibodies 
(mAbs) for research purposes. A major part of this unique collection can be used to investigate the 
functions of viruses that are widely spread among the world’s population. CAPRI has also generated 
a set of mAbs against surface receptors on human and mouse lymphocytes. These mAbs are fully 
characterised and ready for market entry. In addition, CAPRI has several research projects based on its 
mAbs, with the potential to develop new and innovative products.
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2 OBJECTIVES
Utilise the generated antibodies for research, diagnostic and therapeutic applications.
Increase the visibility and awareness of business stakeholders about science-business interaction 
opportunities.
3 APPROACH & METHODS
General approach
CAPRI was established with the focus on production and purification of recombinant proteins and 
mAbs against viral and cellular proteins. The goal of the CAPRI’s spin-off project is to commercialise the 
available research products and attract grant funds for new and existing products from CAPRI’s mAb 
portfolio.
Methods
1. Custom mAbs/hybridoma development 
 Protein (immunogen) production via His-tag and GST-tag purification from E. Coli and Fc-fusion 
protein production in eukaryotic cells
2. Construction of recombinant proteins (potential therapeutics based on mAbs)
3. Construction of new protein and RNA expression vectors
4. In vivo  methods (state of the art animal facility with the impressive collection of genetically modified 
mice with alterations in various aspects of immune response)
4 RESULTS
Figure 1: Varicella proteins visualized in the cell culture and in the human skin and ganglium using our unique mAbs
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Figure 2: CAPRI’s mAb bank
5 POTENTIAL NEW PRODUCTS & SERVICES
1. The collection of mAbs against ~100 target proteins, such as immune cell receptors, their ligands 
and viral proteins. For most of these protein targets there are no other antibodies available anywhere 
in the world. 
2. Innovative recombinant immunotherapeutics
3. Immunotoxin for treatment of glioblastoma multiforme
4. Immunotherapeutic for bridging  the  innate  and  the  specific  antiviral  response
5. New strong viral promotor
Center for Proteomics has produced, purified and packed its mAbs according to the standardised 
protocols, generated a web platform offering its mAb collection and supporting each mAb with the 
corresponding data sheet file.
The database is available at : http://products.capri.com.hr/
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6 CURRENT COLLABORATIONS
In the mAb development Center for Proteomics currently collaborates with the numerous research 
institutions:
1. University of Alabama, Birmingham, USA 
2. Medical University, Innsbruck, Austria
3. Max von Pettenkofer Institute, LMU, Munich, Germany
4. National Institutes of Health (NIH), USA 
5. Heinrich-Heine University, Duesseldorf, Germany
6. Medical School, Hannover, Germany
7. Laboratory of Immunology, NIAID, Maryland, USA
8. Ruhr-Universitat Bochum, 
9. Medizinisches Proteom-Center, Germany
10. Robert Koch-Institute, Berlin, Germany
11. The Rudjer Boskovic Institute, Zagreb, Croatia
7 CONTACT OR COLLABORATIONS NEEDED
Center for Proteomics is interested in future collaboration with companies/institutes or consultants 
with extensive experience in GMP and SOP practices in the field of large scale biopharmaceutical 
production.
8 COMMUNICATION TOOLS
Selected relevant publications  2013:
1. Lenac Rovis T et al. A comprehensive analysis of varicella zoster virus proteins using a new 
monoclonal antibody collection. Journal of Virology, 2013
2. Juranic Lisnic V et al. Dual Analysis of the Murine Cytomegalovirus and Host Cell Transcriptomes 
Reveal New Aspects of the Virus-Host Cell Interface. PLoS Pathogens, 2013
3. Trsan T et al. Superior induction and maintenance of protective CD8 T cells in mice infected with 
MCMV vector expressing RAE-1γ. PNAS, 2013
More on current research projects can be found on: http://www.capri.com.hr
Contact details:
E-mail: info@capri.com.hr
Telephone: +385 51 651 260
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9 FUNDS NEEDED
Forecast on the basis of three years
9.1.  For applied research on mAb bank exploitation 
 (solutions for real-world problems): 100.000 €
9.2   For  ongoing basic research on recombinant immunotherapeutics    
 (investigation of biological mechanisms): 350.000 €
9.3  For  subsequent pilot & demonstrator activities (to develop a prototype):   
 50.000 €
10 CONCLUSION
CAPRI will continue developing its antibody portfolio using the funds granted from various sources. The 
diversification of antibody commercialization processes offers plenty of opportunities for collaborative 
projects with academia and innovative SMEs, including licensing opportunities. Please contact us in 
case you are interested in the presented antibody bank or antibody-based compounds. We also offer a 
full-service development of new and reliable custom-made monoclonal antibodies.
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